Navigation Links
Merriman Capital to Host Pressure BioSciences, Inc. Investor Call at 4:30 p.m. EST on Thursday, December 12, 2013
Date:12/11/2013

SOUTH EASTON, Mass., Dec. 11, 2013 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Merriman Capital, Inc. ("Merriman"), a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), will host an investor call for PBI on Thursday, December 12, 2013 at 4:30 p.m. EST. Pressure BioSciences CEO Richard T. Schumacher and Board Chairman Jeffrey N. Peterson will provide an update on the Company, including a review of the achievements of 2013 and stated goals for 2014, via a webcast with an accompanying PowerPoint presentation.

All investors and interested parties are welcome to join the conference call and webcast. A question and answer session will follow the opening remarks and presentation.  Mr. Schumacher, Mr. Peterson, and board members Mr. Vito Mangiardi, Mr. Kevin Pollack, and Dr. Mickey Urdea will be available during the Q&A session.

Conference Call, Webcast and Presentation Information

Date:  Thursday, December 12, 2013
Time:  4:30 PM Eastern Standard Time (EST)

To listen to this teleconference via telephone (whether or not watching the webcast):
Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 (Canada); (302) 607-2001 (International)
Passcode: VS87265      Conference ID: 865561

To view the webcast, use the following conference link (NOTE: you must use the call-in number above for the audio portion of the webcast):    http://www.join.me/pbio.investormeeting.M1.

The PBIO presentation will be available for viewing and downloading as of 10 a.m. EST, Thursday, December 12, 2013 on the Company's website:    http://www.pressurebiosciences.com.

For those unable to participate in the live teleconference, a replay will be available approximately one hour after the call and will be accessible through the Company's website for 30 days. 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT").  PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market.  PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions.  PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

About Merriman Capital, Inc.

Merriman Capital, Inc. is a full service investment bank and Broker-Dealer that facilitates efficient capital formation through a proprietary digital network, as well as Capital Markets Advisory and comprehensive Corporate Brokerage services for public and private companies. The firm also provides equity and options execution services for sophisticated investors and differentiated research for high growth companies. Merriman Capital, Inc. is a wholly owned brokerage subsidiary of Merriman Holdings, Inc. (OTCQX: MERR) and is a leading advisory firm for publicly traded, high-growth companies.

Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) http://www.finra.org/ and the Securities Investor Protection Corporation (SIPC) http://www.sipc.org/.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

           For more information about PBI and this press release, please click on the following website link: 
                                                 Please visit us on: Facebook, LinkedIn, and Twitter.
                                                             http://www.pressurebiosciences.com

Investor Contacts:
Richard T. Schumacher, President & CEO, Pressure BioSciences, Inc.                     (508) 230-1828 (T)
Douglas Rogers, Managing Director, Merriman Capital, Inc.                                      (415) 248-5612 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%;
2. Healthcare Companies Report Stock Price Updates, and Medical System Integration - Research Report on Johnson & Johnson, Geron, Ligand Pharmaceuticals, Masimo, and Capital Senior Living
3. Creekridge Capital Grows Healthcare Sales Team
4. Exagen Diagnostics, Inc. and Capital Royalty Close Financing Transaction
5. Sector Leaders Briefing & Capital Raise News: Muscle Warfare, Baidu, Herblife, Gilead Sciences and ARIAD
6. American Capital Commits $391 Million in the Combination of Cambridge Major Laboratories and AAIPharma Services
7. TVM Capital MENA Announces Affiliation with Bostons Spaulding Rehabilitation Network
8. Sarissa Capital Issues Open Letter Regarding Astex Pharmaceuticals
9. Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States
10. Creekridge Capital Launches Vendor Sales Training Program
11. BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Feb. 22, 2017  Corin Group announced today the ... used to treat patients with both a massive rotator ... The condition, known as cuff tear arthropathy, causes pain ... The Humelock Reversed Shoulder System, which was ... company based near Lyon, France , ...
(Date:2/22/2017)... Research and Markets has announced the addition of the ... to their offering. ... Dermatological conditions are one of the most ... US population suffers from at least one active skin condition. ... has remained saturated with established and generic products. However, the ...
(Date:2/22/2017)... 22, 2017 Research and Markets has ... by Drug Molecule (Biologic, Small Molecule Drugs), By Route of ... Blockers) Outlook 2022" report to their offering. ... The global psoriasis ... 2016-2022 This report provides a detailed analysis of ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent ... those report that family members or friends have also commented about their poor ... loss wear hearing aids. One reason, suggested by 89 percent of American respondents, ...
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the ... event in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show booth ... For the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled pallet ...
(Date:2/22/2017)... Troy, NY (PRWEB) , ... February 22, 2017 , ... ... effort — especially for hospitals and health systems. Smith & Jones’ delves into this ... In this episode, President of Smith & Jones David Vener meets up with social ...
(Date:2/22/2017)... ... ... BrightStar Care Charleston , a home care and medical staffing agency, ... Center on Aging’s Senior Expo on Thursday, March 23, 2017, at the Omar ... in our community. We are thrilled to participate in this event because we believe ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a ... that the patient context (age, illness and life choices) should be dissociated from ... occurrence. In addition, all too often, studies regarding health system performance ...
Breaking Medicine News(10 mins):